Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
5.76 x 1 6.60 x 12
Post-market by (Cboe BZX)
5.90 -0.64 (-9.79%) 01/08/25 [NASDAQ]
5.76 x 1 6.60 x 12
Post-market 5.90 unch (unch) 19:58 ET
Quote Overview for Wed, Jan 8th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.89
Day High
6.70
Open 6.56
Previous Close 6.54 6.54
Volume 1,229,400 1,229,400
Avg Vol 2,327,250 2,327,250
Stochastic %K 77.05% 77.05%
Weighted Alpha -33.25 -33.25
5-Day Change +0.73 (+14.12%) +0.73 (+14.12%)
52-Week Range 2.10 - 14.22 2.10 - 14.22
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 262,591
  • Shares Outstanding, K 44,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -87,370 K
  • EBIT $ -99 M
  • EBITDA $ -100 M
  • 60-Month Beta 0.24
  • Price/Sales 17.83
  • Price/Cash Flow N/A
  • Price/Book 23.80

Options Overview Details

View History
  • Implied Volatility 119.28% ( +15.55%)
  • Historical Volatility 150.72%
  • IV Percentile 69%
  • IV Rank 26.24%
  • IV High 431.36% on 07/18/24
  • IV Low 8.24% on 07/15/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 264
  • Volume Avg (30-Day) 728
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 7,030
  • Open Int (30-Day) 5,653

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.81
  • Number of Estimates 2
  • High Estimate -0.76
  • Low Estimate -0.86
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +20.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.45 +70.77%
on 12/30/24
Period Open: 5.65
7.26 -18.73%
on 01/03/25
+0.25 (+4.42%)
since 12/06/24
3-Month
2.54 +132.28%
on 10/18/24
Period Open: 2.92
7.26 -18.73%
on 01/03/25
+2.98 (+102.05%)
since 10/08/24
52-Week
2.10 +180.95%
on 08/05/24
Period Open: 9.27
14.22 -58.51%
on 02/06/24
-3.37 (-36.35%)
since 01/08/24

Most Recent Stories

More News
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug application (NDA) for its avutometinib/defactinib combo therapy to treat adult patients...

CTMX : 0.9828 (-3.65%)
CSTL : 32.72 (+1.71%)
SPRO : 1.0000 (-4.76%)
VSTM : 5.90 (-9.79%)
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 5.90 (-9.79%)
Verastem: Q2 Earnings Snapshot

Verastem: Q2 Earnings Snapshot

VSTM : 5.90 (-9.79%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 36.7000 (+0.69%)
ONCY : 0.8680 (-5.08%)
VSTM : 5.90 (-9.79%)
CADL : 8.73 (+4.55%)
FGEN : 0.6508 (+4.23%)
REGN : 733.59 (+0.45%)
ONC.TO : 1.30 (+3.17%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.8680 (-5.08%)
ONC.TO : 1.30 (+3.17%)
RHHBY : 36.7000 (+0.69%)
VSTM : 5.90 (-9.79%)
CADL : 8.73 (+4.55%)
FGEN : 0.6508 (+4.23%)
REGN : 733.59 (+0.45%)
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 0.8680 (-5.08%)
ONC.TO : 1.30 (+3.17%)
VSTM : 5.90 (-9.79%)
CTMX : 0.9828 (-3.65%)
BNTX : 122.15 (-3.73%)
FGEN : 0.6508 (+4.23%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 0.8680 (-5.08%)
VSTM : 5.90 (-9.79%)
CTMX : 0.9828 (-3.65%)
BNTX : 122.15 (-3.73%)
FGEN : 0.6508 (+4.23%)
ONC.TO : 1.30 (+3.17%)
Stock Index Futures Rebound from Thursday’s Sell-Off, U.S. Economic Data on Tap

June S&P 500 E-Mini futures (ESM24) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.30% this morning, rebounding from yesterday’s slump prompted by strong U.S. economic data, which...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
GFS : 41.62 (-4.41%)
LYV : 130.31 (+0.52%)
BA : 171.76 (-0.43%)
NVDA : 140.11 (-0.02%)
DELL : 119.31 (-1.62%)
RNO.FP : 45.810 (-2.84%)
VSTM : 5.90 (-9.79%)
ROST : 154.63 (+2.03%)
MGNI : 16.46 (-0.96%)
DD : 74.45 (-0.84%)
Verastem: Q1 Earnings Snapshot

Verastem: Q1 Earnings Snapshot

VSTM : 5.90 (-9.79%)
Verastem: Q4 Earnings Snapshot

Verastem: Q4 Earnings Snapshot

VSTM : 5.90 (-9.79%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 7.24
2nd Resistance Point 6.97
1st Resistance Point 6.44
Last Price 5.90
1st Support Level 5.63
2nd Support Level 5.36
3rd Support Level 4.82

See More

52-Week High 14.22
Fibonacci 61.8% 9.59
Fibonacci 50% 8.16
Fibonacci 38.2% 6.73
Last Price 5.90
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Trading Volume: The most powerful technical indicator in the world